Bright Enterprise Value from 2010 to 2024
| DRUG Stock | USD 39.18 1.07 2.81% |
Enterprise Value | First Reported 2010-12-31 | Previous Quarter 10.9 M | Current Value 10.4 M | Quarterly Volatility 20.7 M |
Check Bright Minds financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bright Minds' main balance sheet or income statement drivers, such as Depreciation And Amortization of 51.8 K, Interest Expense of 21.6 K or Selling General Administrative of 1.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.32. Bright financial statements analysis is a perfect complement when working with Bright Minds Valuation or Volatility modules.
Bright | Enterprise Value |
Latest Bright Minds' Enterprise Value Growth Pattern
Below is the plot of the Enterprise Value of Bright Minds Biosciences over the last few years. Enterprise Value (or EV) is usually referred to as Bright Minds theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Bright Minds Biosciences debt, but would also pocket its cash. Enterprise Value is more accurate representation of Bright Minds value than its market capitalization because it takes into account all of Bright Minds Biosciences existing debt. It is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents. Bright Minds' Enterprise Value historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bright Minds' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 274.15 M | 10 Years Trend |
|
Enterprise Value |
| Timeline |
Bright Enterprise Value Regression Statistics
| Arithmetic Mean | 43,179,309 | |
| Geometric Mean | 35,056,459 | |
| Coefficient Of Variation | 48.01 | |
| Mean Deviation | 17,649,332 | |
| Median | 54,669,720 | |
| Standard Deviation | 20,731,145 | |
| Sample Variance | 429.8T | |
| Range | 51.9M | |
| R-Value | (0.74) | |
| Mean Square Error | 209.6T | |
| R-Squared | 0.55 | |
| Significance | 0 | |
| Slope | (3,429,089) | |
| Total Sum of Squares | 6016.9T |
Bright Enterprise Value History
Other Fundumenentals of Bright Minds Biosciences
Bright Minds Enterprise Value component correlations
Click cells to compare fundamentals
About Bright Minds Financial Statements
Bright Minds stakeholders use historical fundamental indicators, such as Bright Minds' Enterprise Value, to determine how well the company is positioned to perform in the future. Although Bright Minds investors may analyze each financial statement separately, they are all interrelated. For example, changes in Bright Minds' assets and liabilities are reflected in the revenues and expenses on Bright Minds' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Bright Minds Biosciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (0.16) | (0.17) | |
| Enterprise Value Multiple | (0.16) | (0.17) | |
| Enterprise Value | 10.9 M | 10.4 M |
Currently Active Assets on Macroaxis
When determining whether Bright Minds Biosciences is a strong investment it is important to analyze Bright Minds' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bright Minds' future performance. For an informed investment choice regarding Bright Stock, refer to the following important reports:Check out the analysis of Bright Minds Correlation against competitors. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bright Minds. If investors know Bright will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bright Minds listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.63) | Return On Assets (0.29) | Return On Equity (0.52) |
The market value of Bright Minds Biosciences is measured differently than its book value, which is the value of Bright that is recorded on the company's balance sheet. Investors also form their own opinion of Bright Minds' value that differs from its market value or its book value, called intrinsic value, which is Bright Minds' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bright Minds' market value can be influenced by many factors that don't directly affect Bright Minds' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bright Minds' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bright Minds is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.